Pharmacogenomic biomarkers in oncology: evidence, clinical utility, and barriers to implementation [0.03%]
肿瘤学中关于药物基因组生物标志物的证据、临床实用性和应用障碍
Satyam Kumar Vishwash,Ram Babu Soni,Sourabh Kosey et al.
Satyam Kumar Vishwash et al.
Interpatient variability in chemotherapy response and toxicity remains a major challenge in oncology. Pharmacogenomics (PGx) is an approach to address this challenge by combining somatic alterations that affect tumour sensitivity with germl...
Clinical efficacy and safety profile of long-acting lipoglycopeptides versus daily intravenous antibiotics for acute bacterial skin and skin structure infections (ABSSSI): a retrospective study in Greece [0.03%]
长效脂糖肽类与每日静脉注射抗生素治疗急性细菌性皮肤和皮肤结构感染（ABSSSI）的临床疗效及安全性：希腊的一项回顾性研究
Vasileios Petrakis,Andreas G Tsantes,Petros Rafailidis et al.
Vasileios Petrakis et al.
Background: The rising prevalence of antimicrobial resistance poses a significant challenge in clinical practice, with long-acting lipoglycopeptides (LGPs) offering an attractive alternative to conventional daily intraven...
Efficacy and safety of TROP2 antibody-drug conjugate-containing regimen in the patients with HER2 negative metastatic breast cancer and advanced non-small-cell lung cancer [0.03%]
针对HER2阴性转移性乳腺癌和晚期非小细胞肺癌患者的TROP2抗体药物偶联物疗效及安全性研究
Yangqingqing Zhou,Wunan Huang,Hui Wang et al.
Yangqingqing Zhou et al.
The aim of this study is to evaluate the efficacy and safety of TROP2 antibody-drug conjugate (ADC) -based regimen in the treatment of HER2-negative advanced breast cancer and non-small cell lung cancer (NSCLC) in real environment to fill t...
Efficacy and safety of PD-1/PD-L1 inhibitor-combined chemotherapy versus chemotherapy alone in extensive-stage small-cell lung cancer: a meta-analysis [0.03%]
程序性死亡受体-1及其配体-1抑制剂联合化疗与单纯化疗治疗广泛期小细胞肺癌的疗效和安全性：一项系统综述和.meta.分析
Qiuyi Li,Dan Yan,Wei Li et al.
Qiuyi Li et al.
This study aimed to evaluate the safety and efficacy of PD-1/PD-L1 ICI plus chemotherapy versus chemotherapy alone in ES-SCLC, following PRISMA guidelines.23 studies(10RCTs,13RWSs) with 6364 patients were enrolled,with OS,PFS,ORR and grade ...
A 1:1:1 propensity score matching design to account for center-specific antimicrobial treatment or prophylaxis in observational studies: the case of the POSACOVID study [0.03%]
POSACOVID研究中用于观察性研究的中心特异性抗菌药物治疗或预防的1：1：1倾向评分匹配设计：案例分析
Cristina Marelli,Daniele Roberto Giacobbe,Alessio Signori et al.
Cristina Marelli et al.
Propensity score matching (PSM) is employed in observational studies to reduce confounding by baseline characteristics. We considered a scenario where one center administered a given treatment/prophylaxis, and two other centers provided sta...
Eravacycline in sepsis complicated by Clostridioides difficile infection: a brief case series [0.03%]
埃拉瓦西林治疗由难辨梭状芽孢杆菌感染引起的脓毒症：3例简短报告
Federico Giovagnorio,Giovanni Del Fabro,Agnese Zanus-Fortes et al.
Federico Giovagnorio et al.
Clostridioides difficile infection complicating severe bacterial infections presents a therapeutic challenge, when antimicrobial discontinuation is unfeasible. Eravacycline, a synthetic fluorocycline with broad-spectrum activity against Gra...
Apatinib combined with capecitabine plus temozolomide versus sunitinib in advanced gastroenteropancreatic neuroendocrine tumours: a propensity score-matched real-world study [0.03%]
阿帕替尼联合卡培他滨和替莫唑胺与舒尼替尼治疗晚期胃肠胰神经内分泌肿瘤的疗效：一项倾向评分匹配的真实世界研究
Tiegang Li
Tiegang Li
Apatinib combined with CAPTEM (capecitabine plus temozolomide) has demonstrated preliminary activity in neuroendocrine tumours, yet head-to-head comparative efficacy data against standard-of-care sunitinib remain lacking. This study aims to...
Pharmacokinetic/pharmacodynamic optimization of antimicrobial therapy in neutropenic sepsis: a comprehensive review [0.03%]
抗微生物治疗中性粒细胞减少症合并脓毒血症的药代动力学/药效学优化：全面综述
Bin Qiu,Jianjiang Huang,Fang Zhang et al.
Bin Qiu et al.
Neutropenic sepsis remains a life-threatening complication in patients undergoing cytotoxic chemotherapy or haematopoietic stem cell transplantation. A comprehensive literature search was conducted across PubMed, Embase, and the Cochrane Li...
Cefiderocol for Stenotrophomonas maltophilia infections: real-world evidence from a multicenter study and a comprehensive literature review [0.03%]
头孢狄罗治疗产碱杆菌属感染：多中心研究的真实世界证据及全面文献回顾
Michela Comi,Giulia Mancarella,Silvia Di Bari et al.
Michela Comi et al.
Stenotrophomonas maltophilia is an opportunistic multidrug-resistant pathogen increasingly associated with severe infections. Although cefiderocol has demonstrated potent in-vitro activity against S. maltophilia, clinical evidence remains l...
Cefiderocol susceptibility in carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia isolates: concordance of disk diffusion with the reference method and comparative analysis of CLSI-EUCAST criteria [0.03%]
头孢迪罗对碳青霉烯类耐药的产超广谱β-内酰胺酶肠杆菌科细菌、不动杆菌属和铜绿假单胞菌分离株的体外抗菌活性：与参考方法的一致性及CLSI-EUCAST breakpoint折点标准比较分析
Esra Saylam,Betul Cetin,Fatma Kalem et al.
Esra Saylam et al.
This study investigated the in vitro activity of cefiderocol against Acinetobacter baumannii, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia isolates, comparing disk diffusion (DD) and broth microdilution (BMD) methods. 145 isolat...